All News

Telemedicine.MD.Computer.phone (keep)

Telemedicine Outcomes in RA Care

d Jack Cush, MD

A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).

Read Article
FDA.jpg (keep)

FDA Hearing on COVID-19 Vaccines

d Jack Cush, MD

Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve

Read Article
podcast logo

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article
burnout work overworked

High Burnout Rates Among Rheumatologists

d Jack Cush, MD

Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.

Read Article
COVID.virus_.corona.jpg (keep)

Remdesivir FDA Approved for Hospitalized COVID-19

d Jack Cush, MD

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Read Article
Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)

Dr. John Cush RheumNow ( View Tweet)

Safety of nintedinib (NIN)in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%. RCT discontinuation in 16% & 8.7% https://t.co/v5NxwlHu37

Links:

Dr. John Cush RheumNow ( View Tweet)

PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz https://t.co/lnXrf12tjA

Links:

Dr. John Cush RheumNow ( View Tweet)

Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr. Jack Cush discusses triage Rheumatology; Im Not Stupid; & Swollen but Not Painful iTunes https://t.co/FHJv01Sb3a SoundCloud https://t.co/fceBeXGu09

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Back Talk: Taking Calls ^ Questions from Listeners - watch it here>https://t.co/KuTtu5JawO or listen to the Podcast on iTunes> https://t.co/FHJv01AAbC OR SoundCloud> https://t.co/ICukowi11u

Links:

Dr. John Cush RheumNow ( View Tweet)

Population study of 11 million, shows incidence of OPTIC NEURITIS is 3.7 /100K Pt-Yrs. Strongest association with multiple sclerosis (MS) and weaker associations with Behçet disease, sarcoidosis, and Sjögren syndrome. https://t.co/LVw0fcq1F1

Links:

Dr. John Cush RheumNow ( View Tweet)

Randomized trial of 491 probable nonhospitalized COVID-19 pts shows that HCQ (given 800 mg, followed by 600 mg in 6 -8 hrs, then 600 mg qd x 4d) or placebo shows no reduction in symptom severity in outpatients with early, mild COVID-19.https://t.co/yVWGRr6jfr

Links:

Dr. John Cush RheumNow ( View Tweet)

How are you consuming Virtual CME Rheumatology conferences

Dr. John Cush RheumNow ( View Tweet)

Working on an Endocarditis for the Rheumatologist podcast. fast facts!!! 1️⃣ 20% no fever 2️⃣ 20% joint pain at presentation 3️⃣ >40% splenomegly 4️⃣ 90% anemia 5️⃣ most common rash = petechiae (Osler node/janeway/Roth spots 10% combined!) #rheumatology #cleclinicrheum #immunology

Adam J Brown AdamJBrownMD ( View Tweet)

FDA approved its 1st drug to treat COVID-19 - the antiviral drug Veklury (remdesivir) for for acute care treatment of COVID-19 requiring hospitalization. Approval based on 3 clinical trials showing clinical improvement, but no change in mortality rates. https://t.co/IrA7oKMuGq

Links:

Dr. John Cush RheumNow ( View Tweet)

Study from China finds that hemophagocytic lymphohistiocytosis (HLH) was a rare (4.2%) but fatal (77.8%) complication in myositis patients (DM, PM, or CADM). Risk factors include baseline Dz activity, worsening ILD and infection https://t.co/QDN1DYzl5p

Links:

Dr. John Cush RheumNow ( View Tweet)

How are you consuming Virtual CME Rheumatology conferences

Dr. John Cush RheumNow ( View Tweet)

Study from NY shows that Death rates from COVID-19 have dropped (in hospitalized pts) from a high of 27% down to 3%. Partly because a younger, healthier are now getting infected, arriving @ hospital w/ less-severe Sxs. Also improved COVID medical care https://t.co/8aFuVHUDjY

Links:

Dr. John Cush RheumNow ( View Tweet)

#LTF Listen to Fauci

Dr. John Cush RheumNow ( View Tweet)

Korea National Health databased looked at Fracture rates in RA patients taking TNFis, abatacept, or tocilizumab betw 2002 to 2016. They found no difference in Fx risk related to the biologic taken. https://t.co/W2dWWseXTc

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×